Perlecan Heparan Sulfate Proteoglycan Is a Critical Determinant of Angiogenesis in Response to Mouse Hind-Limb Ischemia

Beiping Qiang, Sang Yeob Lim, Michael Lekas, Michael A. Kuliszewski, Rafael Wolff, Azriel B. Osherov, Dmitriy Rudenko, Howard Leong-Poi, Hossein Noyan, Mansoor Husain, Kiet Tran, Karl Tryggvason, Ulf Hedin, Karin Tran-Lundmark, Bradley H. Strauss

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Perlecan is a heparan sulfate proteoglycan (HSPG) constituent of the extracellular matrix with roles in cell growth, differentiation, and angiogenesis. The role of the HS side chains in regulating invivo angiogenesis after hind-limb ischemia is unknown. Methods: Heparan sulfate (HS)-deficient perlecan (Hspg2δ3/δ3) mice (n= 35), containing normal perlecan core protein but deficient in HS side chains, and wild-type (n= 33) littermates underwent surgical induction of hind-limb ischemia. Laser Doppler perfusion imaging (LDPI) and contrast-enhanced ultrasonography (CEU) provided serial assessment of hind-limb perfusion. Harvested muscles underwent immunostaining for endothelial cell density (CD31), real-time reverse transcription polymerase chain reaction RT-PCR for vascular endothelial growth factor (VEGF) mRNA expression and western blot analysis for VEGF and fibroblast growth factor (FGF)2 protein expression at days 2 and28. Results: Serial LDPI showed significantly greater perfusion recovery in ischemic limbs of wild-type compared with Hspg2δ3/δ3 mice. CEU showed that normalized microvascular perfusion was increased in wild-type compared with Hspg2δ3/δ3 mice at day 28 (0.67 ± 0.12 vs 0.26 ± 0.08; P= 0.001). CD31-positive cell counts were significantly higher in wild-type compared with Hspg2δ3/δ3 mice on day 28 (122 ± 30 cells vs 84 ± 34 cells per high-power field [HPF]; P < 0.05). Endogenous VEGF mRNA expression (P < 0.05) and VEGF protein expression (P < 0.002) were significantly decreased in the ischemic limbs of Hspg2δ3/δ3 mice compared with wild-type mice at day 2 and day 28, respectively. FGF2 protein expression showed no significant differences. Conclusions: These results suggest that the HS side chains in perlecan are important mediators of the angiogenic response to ischemia through a mechanism that involves upregulation of VEGF expression.

Original languageEnglish
Pages (from-to)1444-1451
Number of pages8
JournalCanadian Journal of Cardiology
Volume30
Issue number11
DOIs
Publication statusPublished - 2014 Jan 1

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Perlecan Heparan Sulfate Proteoglycan Is a Critical Determinant of Angiogenesis in Response to Mouse Hind-Limb Ischemia'. Together they form a unique fingerprint.

  • Cite this

    Qiang, B., Lim, S. Y., Lekas, M., Kuliszewski, M. A., Wolff, R., Osherov, A. B., Rudenko, D., Leong-Poi, H., Noyan, H., Husain, M., Tran, K., Tryggvason, K., Hedin, U., Tran-Lundmark, K., & Strauss, B. H. (2014). Perlecan Heparan Sulfate Proteoglycan Is a Critical Determinant of Angiogenesis in Response to Mouse Hind-Limb Ischemia. Canadian Journal of Cardiology, 30(11), 1444-1451. https://doi.org/10.1016/j.cjca.2014.06.003